Interview 8 May 2017 Meet the co-developer of the first commercial mAb and gene therapy Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the first commercial monoclonal antibody, Remicade, and the first market-approved gene therapy, Glybera. I was curious to know what he did to achieve such an impressive track record. Sander van Deventer was trained as an internist […] May 8, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
Startup Scout 28 Apr 2017 This Dutch Biotech Could Boost Gene Editing of Primary Cells Located in the charming town of Utrecht in the Netherlands, Ntrans Technologies was newly founded in 2015 based on a cutting-edge intracellular delivery technology developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. Mission: NTrans is developing the iTOP technology for its use in research and as a therapeutical platform for the delivery of bioactive molecules into […] April 28, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2017 BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, […] April 26, 2017 - 1 minutemin - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 EMA designates uniQure’s gene therapy for hemophilia a priority Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial failure, uniQure has been on the rebound. The company recently has undergone several management shakeups and a strategy review, and it just made the decision to withdraw […] April 25, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2017 Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn The excitement about the therapy was undercut when it became clear Glybera would be a commercial failure. In October, it will officially be dead. uniQure has announced that it will not go for the renewal of its marketing authorization for Glybera in Europe, which is set to expire in October this year. Since Glybera missed approval in the […] April 20, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2017 Huge Successful €103M IPO for the Next European Leader in Bioplastics Avantium has gone public and raised €103M on Euronext Amsterdam and Euronext Bruxelles with Sofinnova Partner as the main shareholder. Avantium, a spin-off from Shell, is developing renewable bioplastics made 100% from plant-based materials with the support of big partners such as Coca-Cola or Danone, for which the Dutch biotech is developing sustainable PlantBottles and yogurt cups, […] March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 1 Mar 2017 Lab-Grown Meat Could Hit the Market as Soon as 2020 Cultured meat could be a sustainable, healthy and inexpensive food alternative in a future that might be closer than we think. We recently attended the 2nd International Conference on Cultured Meat, where we had the chance to meet the key players in this revolutionary field. There, we learned that cultured meat, grown in the lab without […] March 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2017 Gene Therapy for Rheumatoid Arthritis gets Approval to Start Clinical Trials Arthrogen will start a Phase Ib trial for a gene therapy aiming to treat rheumatoid arthritis with a single injection and reduce costs for patients. Arthrogen, based in Amsterdam, is developing local gene therapies for inflammatory diseases. The biotech company has now announced it has received approval to start a Phase Ib trial with its lead […] February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2017 A Dutch University Hospital has Halted Amyloid Beta Drug Studies Despite the popularity of amyloid beta-targeting drugs, none have managed to pass late stage clinical trials, prompting UMC Radboud to halt its own studies. In the latest blow to the amyloid beta hypothesis, Radboud University Medical Centre in Nijmegen, the Netherlands, announced that it will no longer continue studies into drugs targeting misfolded amyloid beta. These […] February 10, 2017 - 3 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy for hemophilia. Now, the FDA has granted Breakthrough Therapy Designation to its candidate AMT-060 for hemophilia B. This is awarded to selected therapies that have […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2017 Dutch Biotech Takes over Sustainable Coca Cola Bottles Project Avantium has acquired Liquid Light, getting hold of the last piece of technology it requires to create the next generation of sustainable Coca Cola bottles. Avantium, a spin-off from Shell located in Amsterdam, is one of Coca Cola’s choices to develop its next-generation plastic bottles made 100% from plant-based materials. The biotech is now stepping up […] January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 9 Jan 2017 After a Rough Year, uniQure CMO discusses a Comeback Last year was a bad year for biotech as an industry, but it was particularly bad for uniQure. Here’s what its CMO has to say about the company’s recovery. After giving the world its first gene therapy, uniQure has hit a series of rough patches since it rose to stardom as one of biotech’s success stories. […] January 9, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email